Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
07. Februar 2024 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy,...
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
24. Januar 2024 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altamira’s polyKRASmut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic...
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
08. Januar 2024 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit Altamira’s two flagship programs, AM-401 and AM-411,...
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
29. Dezember 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing...
Altamira Therapeutics Provides Investor and Business Update
11. Dezember 2023 08:00 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ETPartial spin-off of Bentrio® business first step in transition to...
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
05. Dezember 2023 12:54 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing...
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
29. November 2023 10:20 ET
|
Altamira Therapeutics Ltd
- Partial spin-off of Bentrio® completed to increase focus on RNA delivery activities - Retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue HAMILTON, BERMUDA, Nov. 29,...
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
17. November 2023 09:04 ET
|
Altamira Therapeutics Ltd
Initiates Strategic Repositioning to Focus on Company’s Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue ...
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
10. November 2023 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing...
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
14. September 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Fresh data from randomized controlled NASAR clinical trial further demonstrate efficacy and tolerability of Bentrio® nasal spray in...